Jonathan D Schwartz, MD received his medical degree from Washington University (St Louis, USA) in 1992 and completed internal medicine residency training at Mt Sinai Medical Center (NY, USA) in 1995, with an additional year as Chief Medical Resident. He completed hematology-oncology fellowship at New York Presbyterian Hospital (Weill Cornell Medical Center, NY USA) in 1999 and subsequently served on the faculty at Mt Sinai Medical Center 1999-2006. As an Assistant and subsequent Associate Professor, Dr Schwartz pursued translational research on cytokine networks and angiogenesis in hepatobiliary cancer, and was the recipient of a 5-year NIH K23 award. In addition to the translational and clinical research and a large hepatobiliary/gastrointestinal cancer practice, Dr. Schwartz served as Hematology-Oncology Fellowship Program Director and Co-Director, and developed extensive curricula in gastrointestinal malignancies and anti-neoplastic therapies.

As a Senior Director, Associate Vice President and Vice President of ImClone Systems/Eli Lilly 2006-2014, Dr. Schwartz oversaw the development of Ramucirumab from end-of-phase 1 through phase 3, culminating in EMA, FDA and PMDA approvals in gastric, hepatocellular and other cancers. Dr. Schwartz also oversaw initial clinical investigation of several additional therapeutic antibodies.

As founding Chief Medical and current Chief Scientific Gene Therapy Officer at Rocket Pharmaceuticals, Dr. Schwartz participated significantly in the IND enabling research and applications for Rocket’s lentiviral programs (RP-L102 in Fanconi anemia; RP-L201 in LAD-I; RP-L301 in PKD) and Rocket’s AAV programs (RP-A501 in Danon disease; RP-A601 in PKP2-ACM; RP-A-701 in BAG3-DCM). He has led the design, oversight and interpretation of multiple phase 1 and registrational clinical gene therapy programs in hematologic, immunologic and cardiovascular disorders, and actively participates in international collaborations to optimize the safety, efficacy and accessibility of transformative gene therapies.

Dr. Schwartz has authored/co-authored more than 50 peer-reviewed publications, and more than 90 presentations/abstracts at international medical and scientific meetings.